Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Aminosalicylates probably leads to higher acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cause‐mortality · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Febrile patients and episodes · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower febrile patients and episodes compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Bacteraemia · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower bacteraemia compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).
1 finding from 1 review
Minor bleeding · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in minor bleeding compared with tinzaparin (low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with direct oral anticoagulants (DOAC) (very low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Very low
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in high‐grade cervical intraepithelial neoplasia, adenocarcinoma in… compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found